Farhan Ahmed, MD
Critical Care Medicine · Winston Salem, NCNPI 1396978797
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.4%), education and food and beverage — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Boehringer Ingelheim at 52.3% of the total. 2025 is the largest year on record at $10,253, more than ten times the $530 reported in 2019. Among critical care medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $130.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$9K
- Intuitive Surgical$6K
- United Therapeutics Corporation$338
- GSK$267
- AstraZeneca$185
- Pulmonx Corporation$142
- plus $1K from 29 others
Across 16 payments — averaging $3188.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Verona Pharma, Inc.$35K
- AstraZeneca$17K
What the payments were for
- Consulting fees$7,35043%
- Travel & lodging$2,61115%
- Food & beverage$2,96318%
- Education$4,00024%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 22 | $8,845 |
| Intuitive Surgical | 14 | $6,063 |
| United Therapeutics Corporation | 7 | $338 |
| GSK | 19 | $267 |
| AstraZeneca(2 entities) | 13 | $185 |
| Pulmonx Corporation | 1 | $142 |
| Philips North America LLC | 3 | $102 |
| Medtronic | 1 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Mylan Specialty L.p. | 5 | $76 |
| Inogen, Inc. | 6 | $76 |
| Merck | 5 | $73 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Actelion Pharmaceuticals US, Inc. | 3 | $52 |
| Verona Pharma, Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Abiomed | 1 | $38 |
| Pfizer | 2 | $36 |
| Novartis | 2 | $34 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $26 |
| Sanofi | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Baxter Healthcare | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Shionogi Inc | 1 | $15 |
| Electromed, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Phadia US Inc. | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,924 in reported general payments places this provider in the 90th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $182,984 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 173 | $121,442 |
| Breo ElliptaFluticasone/Vilanterol | 94 | $42,329 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $20,242 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $17,435 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $13,440 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $12,994 |
| Spiriva RespimatTiotropium Bromide | 20 | $10,511 |
| Spiriva HandihalerTiotropium Bromide | 11 | $9,852 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,459 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $3,051 |
| Ventolin HfaAlbuterol Sulfate | 32 | $1,765 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,157 |
| Montelukast Sodium | 89 | $444 |
| Fluticasone Propionate | 41 | $346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $8,845 | $210,93159 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $267 | $177,211289 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $185 | $33,23645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Winston Salem
- Ashish KhannaWinston Salem$364K
- Hassan YousafWinston Salem$97K
- Benjamin BregmanWinston Salem$11K
- Jason ThomasonWinston Salem$7K
- Sean MurphyWinston Salem$6K
- David DefeoWinston Salem$6K
- Romel GobunsuyWinston Salem$2K
- Philip KeithWinston Salem$2K
- Blair BrownWinston Salem$2K
- Gregory RossWinston Salem$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.